Grünenthal GmbH

Tweet this page
<
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
>
Registration as it was on 08 Mar 2016
How to read and use this data card.
Download this datacard

Overview

WARNING: As this organisation lists one or more EP accredited lobbyists, it may not be probable that its lobbying costs are lower than €10,000.

Lobbying Costs

9,999€

Financial year: Jan 2015 - Dec 2015

Lobbyists (Full time equivalent)

1 Fte (2)

Lobbyists with EP accreditation

1

High-level Commission meetings

0

Lobbying Costs over the years

  • Info

    Grünenthal GmbH   (Grünenthal)

    EU Transparency Register

    67826544528-01 First registered on 14 Nov 2010

    Goals / Remit

    The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. We are an entrepreneurial specialist delivering true benefits to patients. By sustainably investing in research and development above the industrial average, we are committing to innovation in order to treat unmet medical needs and bring value-adding products to markets.

    Grünenthal is one of five remaining research-oriented pharmaceutical companies with headquarters in Germany which sustainably invests in research and development. Research and development costs amounted to about 20 percent of revenues in 2014. Grünenthal's research and development strategy concentrates on selected fields of therapy and state-of-the-art technologies. We are intensely focused on discovering new ways to treat pain better and more effectively, with fewer side-effects than current therapies.

    Altogether, the Grünenthal Group is present in 32 countries with affiliates in Europe, Australia, Latin America and the US. Grünenthal products are sold in more than 155 countries and currently approx. 5,300 employees are working for the Grünenthal Group worldwide. In 2014, Grünenthal achieved revenues of € 1.154 bn

    More information: www.grunenthal.com

    Main EU files targeted

    Grünenthal supports the multistakeholder platform "Societal Impact of Pain" (SIP, http://sip-platform.eu ). Furthermore Grünenthal activities in Brussels deal with issues related to healthcare, pain care, pharmaceuticals, innovation and research and intellectual property.

    Address

    Head Office
    Zieglerstraße, 6
    Aachen D-52099
    GERMANY
  • People

    Total lobbyists declared

    2

    Employment timeLobbyists
    50%2

    Lobbyists (Full time equivalent)

    1

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    1 accreditations were / are live (in bold) for the selected state of 08 Mar 2016

    Name Start date End Date
    Ms Gudula Maria Petersen 14 Jun 2018 14 Jun 2019
    Mr Theodorus Norbertus Maria van Rooij 17 Oct 2017 17 Oct 2018
    Ms Gudula Maria Petersen 12 May 2017 09 May 2018
    Mr Theodorus Norbertus Maria van Rooij 10 Oct 2016 05 Oct 2017
    Ms Gudula Maria Petersen 29 Apr 2016 29 Apr 2017
    Mr Theodorus Norbertus Maria van Rooij 24 Sep 2015 19 Sep 2016
    Mr Konrad Labuschagne 21 May 2014 05 Jun 2015
    Mr Konrad Labuschagne 25 May 2013 21 May 2014
    Mrs Kristina Barinka 02 Mar 2013 29 Mar 2014
    Mr Konrad Labuschagne 19 Jun 2012 17 Jun 2013
    Mr Theodorus Norbertus Maria van Rooij 24 Mar 2012 01 Dec 2012
    Mrs Kristina Barinka 24 Mar 2012 01 Dec 2012

    Complementary Information

    None declared

    Person in charge of EU relations

    Mr Norbert van Rooij (Governmental Affairs and Health Policy)

    Person with legal responsibility

    Mr Eric-Paul Pâques (Chairman of the Corporate Executive Board)

  • Categories

    Category

    II - In-house lobbyists and trade/business/professional associations

    Subcategory

    Companies & groups

  • Networking

    Affiliation

    Grünenthal is a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA)

    Member organisations

    None declared

  • Financial Data

    Closed financial year

    Jan 2015 - Dec 2015

    Lobbying costs for closed financial year

    9,999€

    Other financial info

    None declared

  • EU Structures

    Groups (European Commission)

    None

    ACC

    None

    Groups (European Parliament)

    None

    Communication activities

    None foreseen

    Other activities

    None declared

  • Meetings

    Meetings

    None declared

Download this datacard